Atrion Corp logo

Atrion Corp (ATRI)

Delisted
30 Aug 2024
NASDAQ (NGS) NASDAQ (NGS)
$
459. 92
0
0%
$
1.11B Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
$ 459.92
Previous Close
Day Range
459.92 459.92
Year Range
274.98 503.24
Want to track ATRI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Smaller But Mighty: 3 Small-Cap Stocks for Long-Term Dividend Growth

Smaller But Mighty: 3 Small-Cap Stocks for Long-Term Dividend Growth

Generally speaking, small-cap stocks have market capitalizations below $2 billion. They tend to have stronger growth potential over the long run when compared to bigger companies in their respective industries.

Investorplace | 2 years ago
Atrion's (ATRI) Q2 Earnings Plummet Y/Y on Nordson Merger Costs

Atrion's (ATRI) Q2 Earnings Plummet Y/Y on Nordson Merger Costs

Atrion's (ATRI) Q2 EPS drops to 23 cents, down from $3.73 year over year, as merger-related expenses with Nordson hit profits despite strong revenue growth in MPS and fluid delivery segments.

Zacks | 2 years ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atrion Corporation (NASDAQ: ATRI)'s sale to Nordson Corporation for $460.00 per share in cash. If you are an Atrion shareholder, click here to learn more about your legal rights and options.

Accesswire | 2 years ago
Zacks Initiates Coverage of Atrion With Neutral Recommendation

Zacks Initiates Coverage of Atrion With Neutral Recommendation

Discover why Zacks gives Atrion a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Uncover ATRI's impressive growth in the medical devices market and strong financials, alongside challenges like stiff competition in the medical devices market.

Zacks | 2 years ago